1. Clinical phenomapping and outcomes after heart transplantation
- Author
-
Bakir, Maral, Jackson, Nicholas J, Han, Simon X, Bui, Alex, Chang, Eleanor, Liem, David A, Ardehali, Abbas, Ardehali, Reza, Baas, Arnold S, Press, Marcella Calfon, Cruz, Daniel, Deng, Mario C, DePasquale, Eugene C, Fonarow, Gregg C, Khuu, Tam, Kwon, Murray H, Kubak, Bernard M, Nsair, Ali, Phung, Jennifer L, Reed, Elaine F, Schaenman, Joanna M, Shemin, Richard J, Zhang, Qiuheng J, Tseng, Chi-Hong, and Cadeiras, Martin
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Genetics ,Cardiovascular ,Clinical Research ,Transplantation ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Inflammatory and immune system ,Good Health and Well Being ,Adult ,Aged ,Female ,Follow-Up Studies ,Genetic Markers ,Graft Rejection ,Heart Transplantation ,Humans ,Immunosuppressive Agents ,Male ,Middle Aged ,Phenotype ,Precision Medicine ,Risk Factors ,T-Lymphocytes ,Ubiquitin-Protein Ligases ,fms-Like Tyrosine Kinase 3 ,heart transplantation ,phenomapping ,immunosuppression ,biomarkers ,allograft ,rejection ,Cardiorespiratory Medicine and Haematology ,Surgery ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundSurvival after heart transplantation (HTx) is limited by complications related to alloreactivity, immune suppression, and adverse effects of pharmacologic therapies. We hypothesize that time-dependent phenomapping of clinical and molecular data sets is a valuable approach to clinical assessments and guiding medical management to improve outcomes.MethodsWe analyzed clinical, therapeutic, biomarker, and outcome data from 94 adult HTx patients and 1,557 clinical encounters performed between January 2010 and April 2013. Multivariate analyses were used to evaluate the association between immunosuppression therapy, biomarkers, and the combined clinical end point of death, allograft loss, retransplantation, and rejection. Data were analyzed by K-means clustering (K = 2) to identify patterns of similar combined immunosuppression management, and percentile slopes were computed to examine the changes in dosages over time. Findings were correlated with clinical parameters, human leucocyte antigen antibody titers, and peripheral blood mononuclear cell gene expression of the AlloMap (CareDx, Inc., Brisbane, CA) test genes. An intragraft, heart tissue gene coexpression network analysis was performed.ResultsUnsupervised cluster analysis of immunosuppressive therapies identified 2 groups, 1 characterized by a steeper immunosuppression minimization, associated with a higher likelihood for the combined end point, and the other by a less pronounced change. A time-dependent phenomap suggested that patients in the group with higher event rates had increased human leukocyte antigen class I and II antibody titers, higher expression of the FLT3 AlloMap gene, and lower expression of the MARCH8 and WDR40A AlloMap genes. Intramyocardial biomarker-related coexpression network analysis of the FLT3 gene showed an immune system-related network underlying this biomarker.ConclusionsTime-dependent precision phenotyping is a mechanistically insightful, data-driven approach to characterize patterns of clinical care and identify ways to improve clinical management and outcomes.
- Published
- 2018